Middle East Healthcare Valuation
Is 4009 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 4009 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 4009 (SAR93) is trading above our estimate of fair value (SAR72.92)
Significantly Below Fair Value: 4009 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4009?
Other financial metrics that can be useful for relative valuation.
| What is 4009's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | ر.س8.54b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.2x |
| Enterprise Value/EBITDA | 21.4x |
| PEG Ratio | 2.3x |
Price to Earnings Ratio vs Peers
How does 4009's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 38x | ||
4007 Al Hammadi Holding | 30.4x | 11.8% | ر.س9.1b |
4005 National Medical Care | 34.8x | 14.0% | ر.س8.4b |
4004 Dallah Healthcare | 44.9x | 16.0% | ر.س16.3b |
4002 Mouwasat Medical Services | 41.8x | 14.3% | ر.س27.4b |
4009 Middle East Healthcare | 47.5x | 20.9% | ر.س8.5b |
Price-To-Earnings vs Peers: 4009 is expensive based on its Price-To-Earnings Ratio (47.5x) compared to the peer average (38x).
Price to Earnings Ratio vs Industry
How does 4009's PE Ratio compare vs other companies in the Asian Healthcare Industry?
Price-To-Earnings vs Industry: 4009 is expensive based on its Price-To-Earnings Ratio (47.5x) compared to the Asian Healthcare industry average (22.5x).
Price to Earnings Ratio vs Fair Ratio
What is 4009's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 47.5x |
| Fair PE Ratio | 51.6x |
Price-To-Earnings vs Fair Ratio: 4009 is good value based on its Price-To-Earnings Ratio (47.5x) compared to the estimated Fair Price-To-Earnings Ratio (51.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | ر.س93.00 | ر.س86.77 -6.7% | 25.5% | ر.س113.00 | ر.س42.00 | n/a | 7 |
| Apr ’25 | ر.س89.10 | ر.س86.06 -3.4% | 25.4% | ر.س113.00 | ر.س42.00 | n/a | 7 |
| Mar ’25 | ر.س121.60 | ر.س86.06 -29.2% | 25.4% | ر.س113.00 | ر.س42.00 | n/a | 7 |
| Feb ’25 | ر.س108.20 | ر.س80.06 -26.0% | 24.1% | ر.س107.00 | ر.س42.00 | n/a | 7 |
| Jan ’25 | ر.س90.40 | ر.س74.20 -17.9% | 22.4% | ر.س92.00 | ر.س40.00 | n/a | 7 |
| Dec ’24 | ر.س78.40 | ر.س68.73 -12.3% | 22.8% | ر.س92.00 | ر.س40.00 | n/a | 7 |
| Nov ’24 | ر.س69.40 | ر.س64.16 -7.6% | 25.1% | ر.س92.00 | ر.س35.00 | n/a | 7 |
| Oct ’24 | ر.س59.70 | ر.س63.01 +5.6% | 25.3% | ر.س92.00 | ر.س35.00 | n/a | 7 |
| Sep ’24 | ر.س58.70 | ر.س62.73 +6.9% | 26.3% | ر.س92.00 | ر.س33.00 | n/a | 7 |
| Aug ’24 | ر.س63.20 | ر.س62.68 -0.8% | 28.4% | ر.س92.00 | ر.س33.00 | n/a | 6 |
| Jul ’24 | n/a | ر.س62.68 0% | 28.4% | ر.س92.00 | ر.س33.00 | n/a | 6 |
| Jun ’24 | ر.س58.90 | ر.س37.58 -36.2% | 25.2% | ر.س57.00 | ر.س29.00 | n/a | 6 |
| May ’24 | ر.س39.65 | ر.س33.70 -15.0% | 12.4% | ر.س40.50 | ر.س29.00 | n/a | 5 |
| Apr ’24 | ر.س37.65 | ر.س32.70 -13.1% | 14.7% | ر.س40.50 | ر.س28.00 | ر.س89.10 | 5 |
| Mar ’24 | ر.س33.40 | ر.س29.80 -10.8% | 4.5% | ر.س32.00 | ر.س28.00 | ر.س121.60 | 5 |
| Feb ’24 | ر.س27.55 | ر.س29.64 +7.6% | 4.9% | ر.س32.00 | ر.س28.00 | ر.س108.20 | 5 |
| Jan ’24 | ر.س25.75 | ر.س30.06 +16.7% | 4.5% | ر.س32.00 | ر.س28.22 | ر.س90.40 | 4 |
| Dec ’23 | ر.س27.00 | ر.س30.06 +11.3% | 4.5% | ر.س32.00 | ر.س28.22 | ر.س78.40 | 4 |
| Nov ’23 | ر.س31.30 | ر.س30.06 -4.0% | 4.5% | ر.س32.00 | ر.س28.22 | ر.س69.40 | 4 |
| Oct ’23 | ر.س27.20 | ر.س30.06 +10.5% | 4.5% | ر.س32.00 | ر.س28.22 | ر.س59.70 | 4 |
| Sep ’23 | ر.س32.40 | ر.س30.06 -7.2% | 4.5% | ر.س32.00 | ر.س28.22 | ر.س58.70 | 4 |
| Aug ’23 | ر.س35.05 | ر.س32.06 -8.5% | 13.1% | ر.س40.10 | ر.س28.22 | ر.س63.20 | 5 |
| Jul ’23 | ر.س32.20 | ر.س32.58 +1.2% | 13.9% | ر.س40.10 | ر.س28.22 | n/a | 4 |
| Jun ’23 | ر.س37.95 | ر.س31.58 -16.8% | 17.0% | ر.س40.10 | ر.س26.00 | ر.س58.90 | 4 |
| May ’23 | ر.س36.00 | ر.س31.58 -12.3% | 17.0% | ر.س40.10 | ر.س26.00 | ر.س39.65 | 4 |
| Apr ’23 | ر.س32.45 | ر.س35.22 +8.5% | 16.2% | ر.س40.10 | ر.س26.00 | ر.س37.65 | 4 |
Analyst Forecast: Target price is lower than the current share price.